A new cough syrup contains 15 mg of codeine phosphate and 100 mg of guaifenesin in each 10 mL dose. What would this product likely be classified as?

The correct classification for the cough syrup containing 15 mg of codeine phosphate per 10 mL along with guaifenesin is Schedule V. This classification is based on the concentration of codeine present in the formulation.

According to the Controlled Substances Act, products that contain less than 200 mg of codeine per 100 mL or per 100 grams are generally classified as Schedule V substances. In this case, the codeine concentration is well below the threshold for higher schedules, making it appropriate for Schedule V classification.

Products in this schedule are considered to have a lower potential for abuse compared to those found in higher schedules like Schedule II or III, which contain higher concentrations of controlled substances or combinations that have greater therapeutic effects and higher abuse potential. The inclusion of guaifenesin, an expectorant, further mitigates the potential for abuse, reinforcing the classification of the syrup within Schedule V.